Comparative Pharmacology
Head-to-head clinical analysis: APIDRA SOLOSTAR versus HUMALOG MIX 50 50 KWIKPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APIDRA SOLOSTAR versus HUMALOG MIX 50 50 KWIKPEN.
APIDRA SOLOSTAR vs HUMALOG MIX 50/50 KWIKPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin glulisine is a recombinant human insulin analog that lowers blood glucose by binding to insulin receptors on muscle and fat cells, facilitating glucose uptake, and inhibiting hepatic glucose production.
Insulin lispro is a rapid-acting insulin analog that lowers blood glucose by stimulating peripheral glucose uptake, especially in skeletal muscle and adipose tissue, and by inhibiting hepatic glucose production. It binds to the insulin receptor, activating tyrosine kinase signaling.
Subcutaneous injection, 0.2-0.4 units/kg/day divided into two or more doses; for basal-bolus therapy, total daily dose is 0.5-1.0 units/kg/day with 50-60% as prandial insulin glulisine.
Subcutaneous injection: individualized dose based on metabolic needs, blood glucose monitoring, and prior insulin therapy. Typically administered within 15 minutes before meals or immediately after meals. Total daily dose: 0.5-1.0 units/kg/day in divided doses. For the mix 50/50, half as basal (intermediate-acting component) and half as bolus (rapid-acting component).
None Documented
None Documented
1.0-1.5 hours (terminal elimination half-life; consistent with rapid absorption and clearance; shorter than regular human insulin)
0.5-1 hour (insulin lispro); terminal half-life is approximately 1 hour. Clinically, the rapid clearance allows for flexible dosing timing relative to meals.
Renal: 60-80% of dose as metabolites and parent drug; biliary/fecal: minor (20-40%)
Renal: 60-80% as metabolites; hepatic metabolism accounts for most of the remainder. Fecal excretion is minimal.
Category C
Category C
Insulin
Insulin